-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Zhitong Finance App, Yingpai Pharmaceutical-B (07630.HK) announced that the innovative drug Senapali (Chinese product name: Pai Shuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) and approved for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The approval was made by the European Commission (EC) based on positive opinions from the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP). Since then, senapalil has become the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.
Share
Listen to the news
According to Zhitong Finance App, Yingpai Pharmaceutical-B (07630.HK) announced that the innovative drug Senapali (Chinese product name: Pai Shuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) and approved for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The approval was made by the European Commission (EC) based on positive opinions from the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP). Since then, senapalil has become the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending